
Zydus Lifesciences Limited has informed the Exchange about press release dated 12-Sep-2022 titled Zydus receives final approval and 180 days shared exclusivity from the USFDA for Cariprazine Capsules
Filed with NSE ·

Zydus Lifesciences Limited has informed the Exchange about press release dated 12-Sep-2022 titled Zydus receives final approval and 180 days shared exclusivity from the USFDA for Cariprazine Capsules
6ix hasn’t read this filing yet.
Zydus Lifesciences Limited on 6ix
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences